Precision BioSciences Future Growth
Future criteria checks 0/6
Precision BioSciences's revenue and earnings are forecast to decline at 23.1% and 41% per annum respectively while EPS is expected to decline by 30.6% per annum.
Key information
-41.0%
Earnings growth rate
-30.6%
EPS growth rate
Biotechs earnings growth | 27.6% |
Revenue growth rate | -23.1% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 18 Nov 2024 |
Recent future growth updates
Recent updates
Analysts Just Made A Meaningful Upgrade To Their Precision BioSciences, Inc. (NASDAQ:DTIL) Forecasts
Aug 06It's Down 29% But Precision BioSciences, Inc. (NASDAQ:DTIL) Could Be Riskier Than It Looks
Jun 23Is Precision BioSciences (NASDAQ:DTIL) Using Debt In A Risky Way?
Mar 14Is Precision BioSciences (NASDAQ:DTIL) Weighed On By Its Debt Load?
Dec 08Precision BioSciences appoints chief business officer from within ranks, rejigs co-founders' roles
Sep 02Precision BioSciences: CAR T Data Updates End Of 2022 And Plenty Of Cash
Aug 16Precision BioSciences Q2 2022 Earnings Preview
Aug 05Precision Bio: Another CAR-T Laggard With No Solid Prospects
May 09Despite Lacking Profits Precision BioSciences (NASDAQ:DTIL) Seems To Be On Top Of Its Debt
Apr 19Analyst Forecasts Just Became More Bearish On Precision BioSciences, Inc. (NASDAQ:DTIL)
Mar 21Precision BioSciences (NASDAQ:DTIL) Is Using Debt Safely
Dec 31Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 32 | -59 | 17 | 17 | 3 |
12/31/2025 | 20 | -58 | -7 | -39 | 4 |
12/31/2024 | 71 | -2 | -53 | -20 | 5 |
9/30/2024 | 75 | 11 | -48 | -48 | N/A |
6/30/2024 | 88 | 16 | -66 | -65 | N/A |
3/31/2024 | 58 | -20 | -73 | -72 | N/A |
12/31/2023 | 49 | -43 | -86 | -84 | N/A |
9/30/2023 | 52 | -49 | -100 | -98 | N/A |
6/30/2023 | 47 | -31 | -49 | -45 | N/A |
3/31/2023 | 31 | -59 | -52 | -48 | N/A |
12/31/2022 | 25 | -73 | -49 | -46 | N/A |
9/30/2022 | 21 | -76 | -52 | -48 | N/A |
6/30/2022 | 38 | -93 | -105 | -101 | N/A |
3/31/2022 | 102 | -40 | -113 | -108 | N/A |
12/31/2021 | 116 | -31 | -17 | -11 | N/A |
9/30/2021 | 118 | -32 | -6 | -1 | N/A |
6/30/2021 | 101 | -47 | -4 | 1 | N/A |
3/31/2021 | 34 | -101 | 2 | 7 | N/A |
12/31/2020 | 24 | -109 | -92 | -87 | N/A |
9/30/2020 | 22 | -106 | -104 | -94 | N/A |
6/30/2020 | 19 | -101 | -101 | -86 | N/A |
3/31/2020 | 24 | -88 | -98 | -77 | N/A |
12/31/2019 | 22 | -93 | -96 | -71 | N/A |
9/30/2019 | 21 | -87 | -92 | -63 | N/A |
6/30/2019 | 18 | -76 | -92 | -64 | N/A |
3/31/2019 | 15 | -69 | -77 | -57 | N/A |
12/31/2018 | 11 | -46 | -67 | -52 | N/A |
9/30/2018 | 7 | -38 | -53 | -46 | N/A |
12/31/2017 | 6 | -21 | N/A | -24 | N/A |
12/31/2016 | 7 | -8 | N/A | 92 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: DTIL's earnings are forecast to decline over the next 3 years (-41% per year).
Earnings vs Market: DTIL's earnings are forecast to decline over the next 3 years (-41% per year).
High Growth Earnings: DTIL's earnings are forecast to decline over the next 3 years.
Revenue vs Market: DTIL's revenue is expected to decline over the next 3 years (-23.1% per year).
High Growth Revenue: DTIL's revenue is forecast to decline over the next 3 years (-23.1% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if DTIL's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/22 01:04 |
End of Day Share Price | 2024/12/20 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Precision BioSciences, Inc. is covered by 9 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Konstantinos Biliouris | BMO Capital Markets Equity Research |
Debjit Chattopadhyay | Guggenheim Securities, LLC |
Debjit Chattopadhyay | H.C. Wainwright & Co. |